Biosecurity risks from chatbots, $500M for cell-modeling data, AI-designed recombinases hit pharma, FDA streams trial data in real time, and a literature agent that actually reads the figures.
This week in AIxBio (April 30, 2026)
Biosecurity risks from chatbots, $500M for cell-modeling data, AI-designed recombinases hit pharma, FDA streams trial data in real time, and a literature agent that actually reads the figures.